Papillary carcinomas of the breast: the decisions you may face

Cancer page →Second-opinion finder →

2 treatment settings, 0 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.

Other settings

Encapsulated or solid, no conventional invasion

One path named

Managed as ductal carcinoma in situ: excision, with radiotherapy and endocrine therapy considered.

The path, in plain words

TamoxifenApprovedSmall-molecule SERM

The original targeted cancer drug (1977): a pill that blocks oestrogen's effect on breast cancer and halves recurrence, still essential for premenopausal women.

Also referenced:Ductal carcinoma in situ (DCIS)

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record

Tamoxifen all recorded rates →

Possible QT prolongation. Check ECG and electrolytes; review other QT-prolonging drugs.

Questions to ask about this decision

Is Tamoxifen the only reasonable path for me, or is there a trial, a different sequence or a wait-and-see option?
Why: A single standard does not mean a single choice; timing and trials are decisions too.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
For my situation (encapsulated or solid, no conventional invasion), which of the standard options do you recommend and why?
Why: Guideline options include: Managed as ductal carcinoma in situ: excision, with radiotherapy and endocrine therapy considered.
Am I a candidate for Tamoxifen, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.

Add these to your appointment list, or take the full question set for this cancer.

Other settings

With conventional invasive carcinoma

One path named

Treated as HR-positive breast cancer.

The path, in plain words

Endocrine therapy (SERMs, AIs, SERDs)Standard of care

Pills that block or remove oestrogen signalling, the mainstay of treatment for hormone-driven breast cancer for 50 years.

Oral, effective, cheap (generics)

Also referenced:HR-positive / HER2-negative breast cancer

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record

Endocrine therapy (SERMs, AIs, SERDs)

ESR1 mutations; menopausal symptoms, bone loss, adherence

Questions to ask about this decision

Is Endocrine therapy (SERMs, AIs, SERDs) the only reasonable path for me, or is there a trial, a different sequence or a wait-and-see option?
Why: A single standard does not mean a single choice; timing and trials are decisions too.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
For my situation (with conventional invasive carcinoma), which of the standard options do you recommend and why?
Why: Guideline options include: Treated as HR-positive breast cancer.

Add these to your appointment list, or take the full question set for this cancer.

How to read this page. Options and results come from OnCo records with their sources; the settings are the standard-of-care rows on the cancer page, and the lines of therapy are on the sequencing grid. Where a setting names one path, the choice is usually about timing, trials and where to be treated: see expert centres. OnCo is orientation, not medical advice.

Living with cancer·Standard of care

Papillary carcinomas of the breast: the decisions you may face

Cancer page →Second-opinion finder →

Other settings

Encapsulated or solid, no conventional invasion

One path named

Managed as ductal carcinoma in situ: excision, with radiotherapy and endocrine therapy considered.

The path, in plain words

TamoxifenApprovedSmall-molecule SERM

The original targeted cancer drug (1977): a pill that blocks oestrogen's effect on breast cancer and halves recurrence, still essential for premenopausal women.

Also referenced:Ductal carcinoma in situ (DCIS)

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record

Tamoxifen all recorded rates →

Possible QT prolongation. Check ECG and electrolytes; review other QT-prolonging drugs.

Questions to ask about this decision

Is Tamoxifen the only reasonable path for me, or is there a trial, a different sequence or a wait-and-see option?
Why: A single standard does not mean a single choice; timing and trials are decisions too.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
For my situation (encapsulated or solid, no conventional invasion), which of the standard options do you recommend and why?
Why: Guideline options include: Managed as ductal carcinoma in situ: excision, with radiotherapy and endocrine therapy considered.
Am I a candidate for Tamoxifen, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.

Add these to your appointment list, or take the full question set for this cancer.

Other settings

With conventional invasive carcinoma

One path named

Treated as HR-positive breast cancer.

The path, in plain words

Endocrine therapy (SERMs, AIs, SERDs)Standard of care

Pills that block or remove oestrogen signalling, the mainstay of treatment for hormone-driven breast cancer for 50 years.

Oral, effective, cheap (generics)

Also referenced:HR-positive / HER2-negative breast cancer

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record

Endocrine therapy (SERMs, AIs, SERDs)

ESR1 mutations; menopausal symptoms, bone loss, adherence

Questions to ask about this decision

Is Endocrine therapy (SERMs, AIs, SERDs) the only reasonable path for me, or is there a trial, a different sequence or a wait-and-see option?
Why: A single standard does not mean a single choice; timing and trials are decisions too.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
For my situation (with conventional invasive carcinoma), which of the standard options do you recommend and why?
Why: Guideline options include: Treated as HR-positive breast cancer.

Add these to your appointment list, or take the full question set for this cancer.